Average article processing time (30-45 days)
Less than 5 volumes 30 days
8 - 9 volumes 40 days
10 and more volumes 45 days
Abstract
Neoadjuvant Therapy in Pancreatic Cancer: Review Article
Moritz Pross, Steffen Deichmann, Tobias Keck, Dirk Bausch, Ulrich F Wellne, Kim C Honselmann, Carlo Jung
We performed a literature review for neadjuvant therapy in pancreatic cancer. We divided the results into resectable disease and local advanced pancreatic cancer. Results Neoadjuvant therapy in pancreatic cancer is safe. But currently no standard guidelines exist in neoadjuvant approaches on pancreatic cancer. For local advanced pancreatic cancer the available data tends to show a positive effect on survival rates for neoadjuvant approaches.
